Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Glaxosmithkline Plc Wins U.S. Approval For New Flu Vaccine-Reuters
Reuters reported that U.S. health regulators have approved a new four strain seasonal influenza vaccine made by Glaxosmithkline Plc. The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children age 3 and older and adults against flu virus subtypes A and B contained in the vaccine. Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain.
Latest Developments for GlaxoSmithKline PLC
- Glaxosmithkline Plc Receives Offer For Thrombosis Brands
- FDA Panel Votes To Modify Glaxosmithkline Plc's Avandia Restrictions-Reuters
- Glaxosmithkline Plc and Genmab A/S Announce Positive Top-Line Results From Pivotal Study of ARZERRA Combined With Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approves Two Glaxosmithkline Plc Melanoma Drugs-Reuters
Latest Key Developments in Pharmaceuticals
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet Against House Dust Mite Allergy
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- Share this
- Link this
- Digg this
Follow Reuters